VIDEO: Adagrasib, pembrolizumab shows ‘encouraging’ activity in KRAS G12C-mutated NSCLC
Click Here to Manage Email Alerts
MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.
The KRYSTAL-7 study demonstrated that it’s possible to combine adagrasib (Krazati, Mirati Therapeutics) with pembrolizumab (Keytruda, Merck) in these patients “without major added toxicities,” according to Jänne, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. The response rate was over 60% in the study.
Jänne noted that the development of this combination will move forward into the first-line setting, where there are currently no FDA-approved KRAS G12C inhibitors.
“By combining adagrasib with pembrolizumab, hopefully this is one way to be able to bring KRAS-targeted inhibition into the first-line setting by combining it with standard of care,” Jänne said.
Collapse
Jänne P, et al. Abstract LBA65. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Click Here to Manage Email Alerts